FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2749403818> ?p ?o ?g. }

• W2749403818 abstract "This study evaluated the effectiveness and safety of the egg-based, trivalent, inactivated split influenza vaccine produced by the Institute of Medical Biology, Chinese Academy of Medical Sciences, Peking Union Medical College, China.From March 2012 through May 2012, we enrolled a total of 1390 healthy volunteers between the ages of 3 and 80 years in a randomized clinical trial at the Hebei Disease Control Center Vaccine Clinical Evaluation Center. For all subjects, body part adverse reactions and whole-body adverse reactions were observed 30 min, 6 h, and 1-7 days' post-inoculation. If no severe adverse effects were observed 7 days' post-vaccination, the local and systemic reactions of preliminary test participants were recorded until day 28. There was no placebo group in this study. Blood samples were taken for serological testing before vaccination and 28 days' post-vaccination.Twenty-eight days after vaccination, the seroconversion rates of experimental and control groups were H1N1 75.3% and 75.7%, H3N2 75.8% and 71.8%, B 70.7% vs. 69.4%, (P > 0.05). The antibody Geometric Mean Titer（GMT）of experimental and control groups were H1N1 (179.7, 182.4), H3N2 (584.0, 445.7), B (201.4,191.6). The protection rate of experimental and control groups was not statistically significant (H1N1: 86% vs. 87%, H3N2: 99% vs. 98%, B: 98% vs. 98%). Also, 95% confidence intervals of the protection rate difference between the experimental and the control group were H1N1: -0.1% (-4.1,3.8) %, H3N2: 0.3% (-1.0,1.7) % and B: 0.2% (-1.5,1.9) %; confidence intervals exceeded the limit of -5%. The rates of adverse reactions between experimental and control groups were 6.3% and 7.7% in local response reactions, and 19.5% and 18.0% in systemic reactions. Three hundred and twenty-seven adverse events (AEs) in 1200 (27.76%) subjects were reported within 28 d after vaccination. No serious adverse events occurred during the study.The experimental vaccine three-antibody protection rate was non-inferior to the control vaccine. Our results demonstrated that the experimental vaccine achieved the primary immunogenic end point of the intended clinical protocol, as well as a secondary immunogenic end-point, with an acceptable level of safety. IRB approval for this study was issued under #2012Y0005 and registered as Clinical Trial No. NCT01551810." @default.
• W2749403818 created "2017-08-31" @default.
• W2749403818 creator A5021577866 @default.
• W2749403818 creator A5024843689 @default.
• W2749403818 creator A5027090738 @default.
• W2749403818 creator A5058927188 @default.
• W2749403818 creator A5066306425 @default.
• W2749403818 creator A5090998568 @default.
• W2749403818 date "2017-09-05" @default.
• W2749403818 modified "2023-09-26" @default.
• W2749403818 title "Safety and effectiveness assessment of 2011–2012 seasonal influenza vaccine produced in China: a randomized trial" @default.
• W2749403818 cites W1972512096 @default.
• W2749403818 cites W2006079378 @default.
• W2749403818 cites W2054220360 @default.
• W2749403818 cites W2118668316 @default.
• W2749403818 cites W2131170401 @default.
• W2749403818 doi "https://doi.org/10.1080/00325481.2017.1369133" @default.
• W2749403818 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28825515" @default.
• W2749403818 hasPublicationYear "2017" @default.
• W2749403818 type Work @default.
• W2749403818 sameAs 2749403818 @default.
• W2749403818 citedByCount "3" @default.
• W2749403818 countsByYear W27494038182017 @default.
• W2749403818 countsByYear W27494038182018 @default.
• W2749403818 countsByYear W27494038182022 @default.
• W2749403818 crossrefType "journal-article" @default.
• W2749403818 hasAuthorship W2749403818A5021577866 @default.
• W2749403818 hasAuthorship W2749403818A5024843689 @default.
• W2749403818 hasAuthorship W2749403818A5027090738 @default.
• W2749403818 hasAuthorship W2749403818A5058927188 @default.
• W2749403818 hasAuthorship W2749403818A5066306425 @default.
• W2749403818 hasAuthorship W2749403818A5090998568 @default.
• W2749403818 hasConcept C126322002 @default.
• W2749403818 hasConcept C142724271 @default.
• W2749403818 hasConcept C159654299 @default.
• W2749403818 hasConcept C168563851 @default.
• W2749403818 hasConcept C197934379 @default.
• W2749403818 hasConcept C203014093 @default.
• W2749403818 hasConcept C204787440 @default.
• W2749403818 hasConcept C22070199 @default.
• W2749403818 hasConcept C2522874641 @default.
• W2749403818 hasConcept C27081682 @default.
• W2749403818 hasConcept C2777451964 @default.
• W2749403818 hasConcept C45189115 @default.
• W2749403818 hasConcept C535046627 @default.
• W2749403818 hasConcept C71924100 @default.
• W2749403818 hasConceptScore W2749403818C126322002 @default.
• W2749403818 hasConceptScore W2749403818C142724271 @default.
• W2749403818 hasConceptScore W2749403818C159654299 @default.
• W2749403818 hasConceptScore W2749403818C168563851 @default.
• W2749403818 hasConceptScore W2749403818C197934379 @default.
• W2749403818 hasConceptScore W2749403818C203014093 @default.
• W2749403818 hasConceptScore W2749403818C204787440 @default.
• W2749403818 hasConceptScore W2749403818C22070199 @default.
• W2749403818 hasConceptScore W2749403818C2522874641 @default.
• W2749403818 hasConceptScore W2749403818C27081682 @default.
• W2749403818 hasConceptScore W2749403818C2777451964 @default.
• W2749403818 hasConceptScore W2749403818C45189115 @default.
• W2749403818 hasConceptScore W2749403818C535046627 @default.
• W2749403818 hasConceptScore W2749403818C71924100 @default.
• W2749403818 hasLocation W27494038181 @default.
• W2749403818 hasLocation W27494038182 @default.
• W2749403818 hasOpenAccess W2749403818 @default.
• W2749403818 hasPrimaryLocation W27494038181 @default.
• W2749403818 hasRelatedWork W1506599976 @default.
• W2749403818 hasRelatedWork W2044036053 @default.
• W2749403818 hasRelatedWork W2060873578 @default.
• W2749403818 hasRelatedWork W2192165606 @default.
• W2749403818 hasRelatedWork W2227396938 @default.
• W2749403818 hasRelatedWork W2382824495 @default.
• W2749403818 hasRelatedWork W2415423228 @default.
• W2749403818 hasRelatedWork W2513039084 @default.
• W2749403818 hasRelatedWork W2766571200 @default.
• W2749403818 hasRelatedWork W2793840390 @default.
• W2749403818 hasRelatedWork W2795611591 @default.
• W2749403818 hasRelatedWork W2885803582 @default.
• W2749403818 hasRelatedWork W2994924969 @default.
• W2749403818 hasRelatedWork W3031874085 @default.
• W2749403818 hasRelatedWork W3046409828 @default.
• W2749403818 hasRelatedWork W3048446898 @default.
• W2749403818 hasRelatedWork W3102328262 @default.
• W2749403818 hasRelatedWork W3176374366 @default.
• W2749403818 hasRelatedWork W3202094457 @default.
• W2749403818 hasRelatedWork W4225723258 @default.
• W2749403818 isParatext "false" @default.
• W2749403818 isRetracted "false" @default.
• W2749403818 magId "2749403818" @default.
• W2749403818 workType "article" @default.